Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy?

Axel S. Merseburger, Peter Hammerer, Francois Rozet, Thierry Roumeguère, Orazio Caffo, Fernando Calais da Silva, Antonio Alcaraz*

*Corresponding author for this work
24 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy?'. Together they form a unique fingerprint.

Medicine & Life Sciences